Mike Gallatin, Ph.D. is Senior Advisor to Frazier Healthcare Partners and is Co-founder and Director of Inipharm. Mike has over 35 years of experience as a scientist and executive in the biopharma industry. He has co-founded multiple companies, including Mavupharma (acquired by AbbVie), Calistoga Pharmaceuticals (acquired by Gilead Sciences), and Stromedix (acquired by Biogen Idec). Mike served as President of Calistoga and was one of the founding scientists at ICOS Corporation, where he served as VP and Scientific Director. Earlier, Mike developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Mike has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry. Mike received his Ph.D. from the University of Alberta Department of Immunology.